vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and PennyMac Mortgage Investment Trust (PMT). Click either name above to swap in a different company.
PennyMac Mortgage Investment Trust is the larger business by last-quarter revenue ($93.6M vs $62.1M, roughly 1.5× Cytek Biosciences, Inc.). PennyMac Mortgage Investment Trust runs the higher net margin — 56.0% vs -70.9%, a 126.9% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -13.3%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 12.3%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
PennyMac Mortgage Investment Trust is a U.S.-headquartered real estate investment trust specializing in residential mortgage assets. It invests in performing and non-performing mortgage loans, mortgage-backed securities, and credit risk transfer instruments, operating across investment management and mortgage servicing segments in the U.S. housing market.
CTKB vs PMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $93.6M |
| Net Profit | $-44.1M | $52.4M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 38.6% |
| Net Margin | -70.9% | 56.0% |
| Revenue YoY | 8.1% | -13.3% |
| Net Profit YoY | -557.1% | 12.5% |
| EPS (diluted) | — | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $93.6M | ||
| Q3 25 | $52.3M | $99.2M | ||
| Q2 25 | $45.6M | $70.2M | ||
| Q1 25 | $41.5M | $44.5M | ||
| Q4 24 | $57.5M | $107.9M | ||
| Q3 24 | $51.5M | $80.9M | ||
| Q2 24 | $46.6M | $71.2M | ||
| Q1 24 | $44.9M | $74.2M |
| Q4 25 | $-44.1M | $52.4M | ||
| Q3 25 | $-5.5M | $58.3M | ||
| Q2 25 | $-5.6M | $7.5M | ||
| Q1 25 | $-11.4M | $9.7M | ||
| Q4 24 | $9.6M | $46.5M | ||
| Q3 24 | $941.0K | $41.4M | ||
| Q2 24 | $-10.4M | $25.4M | ||
| Q1 24 | $-6.2M | $47.6M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 38.6% | ||
| Q3 25 | -17.6% | 47.4% | ||
| Q2 25 | -23.3% | 24.2% | ||
| Q1 25 | -36.1% | -14.2% | ||
| Q4 24 | 5.2% | 51.1% | ||
| Q3 24 | -8.2% | 32.8% | ||
| Q2 24 | -18.3% | 40.2% | ||
| Q1 24 | -23.9% | 43.6% |
| Q4 25 | -70.9% | 56.0% | ||
| Q3 25 | -10.5% | 58.7% | ||
| Q2 25 | -12.2% | 10.7% | ||
| Q1 25 | -27.5% | 21.8% | ||
| Q4 24 | 16.8% | 43.1% | ||
| Q3 24 | 1.8% | 51.2% | ||
| Q2 24 | -22.4% | 35.7% | ||
| Q1 24 | -13.8% | 64.2% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | — | $0.55 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $0.45 | ||
| Q3 24 | — | $0.36 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $190.5M |
| Total DebtLower is stronger | — | $1.1B |
| Stockholders' EquityBook value | $341.7M | $1.9B |
| Total Assets | $461.5M | $21.3B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $190.5M | ||
| Q3 25 | $93.3M | $181.0M | ||
| Q2 25 | $75.5M | $108.6M | ||
| Q1 25 | $95.3M | $204.2M | ||
| Q4 24 | $98.7M | $103.2M | ||
| Q3 24 | $162.3M | $102.8M | ||
| Q2 24 | $177.9M | $336.3M | ||
| Q1 24 | $168.8M | $343.3M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $299.0M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $968.4M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | — | $5.1B |
| Q4 25 | $341.7M | $1.9B | ||
| Q3 25 | $378.6M | $1.9B | ||
| Q2 25 | $377.6M | $1.9B | ||
| Q1 25 | $379.6M | $1.9B | ||
| Q4 24 | $395.7M | $1.9B | ||
| Q3 24 | $385.5M | $1.9B | ||
| Q2 24 | $389.1M | $1.9B | ||
| Q1 24 | $392.6M | $2.0B |
| Q4 25 | $461.5M | $21.3B | ||
| Q3 25 | $494.9M | $18.5B | ||
| Q2 25 | $493.3M | $16.8B | ||
| Q1 25 | $482.6M | $14.9B | ||
| Q4 24 | $499.5M | $14.4B | ||
| Q3 24 | $491.2M | $13.1B | ||
| Q2 24 | $483.7M | $12.1B | ||
| Q1 24 | $492.1M | $12.3B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 2.70× | ||
| Q2 24 | — | 2.76× | ||
| Q1 24 | — | 2.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-7.2B |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | -137.76× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-7.2B | ||
| Q3 25 | $-3.9M | $-1.3B | ||
| Q2 25 | $108.0K | $-2.0B | ||
| Q1 25 | $-125.0K | $-594.3M | ||
| Q4 24 | $2.0M | $-2.7B | ||
| Q3 24 | $13.2M | $-983.8M | ||
| Q2 24 | $6.2M | $243.8M | ||
| Q1 24 | $4.0M | $-342.4M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | -137.76× | ||
| Q3 25 | — | -22.26× | ||
| Q2 25 | — | -267.53× | ||
| Q1 25 | — | -61.39× | ||
| Q4 24 | 0.21× | -58.08× | ||
| Q3 24 | 14.05× | -23.76× | ||
| Q2 24 | — | 9.59× | ||
| Q1 24 | — | -7.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
